Your browser doesn't support javascript.
loading
Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center
Bommannan, Karthik; Arumugam, Jhansi Rani; Radhakrishnan, Venkatraman; Kalaiyarasi, Jayachandran Perumal; Mehra, Nikita; Sagar, Tenali Gnana; Sundersingh, Shirley.
  • Bommannan, Karthik; Cancer Institute (W.I.A.). Adyar. IN
  • Arumugam, Jhansi Rani; Cancer Institute (W.I.A.). Adyar. IN
  • Radhakrishnan, Venkatraman; Cancer Institute (W.I.A.). Adyar. IN
  • Kalaiyarasi, Jayachandran Perumal; Cancer Institute (W.I.A.). Adyar. IN
  • Mehra, Nikita; Cancer Institute (W.I.A.). Adyar. IN
  • Sagar, Tenali Gnana; Cancer Institute (W.I.A.). Adyar. IN
  • Sundersingh, Shirley; Cancer Institute (W.I.A.). Adyar. IN
Hematol., Transfus. Cell Ther. (Impr.) ; 44(2): 143-150, Apr.-June 2022. tab, graf
Article in English | LILACS | ID: biblio-1385039
ABSTRACT
Abstract Introduction Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. There is a paucity of studies that have comprehensively analyzed the clinical and laboratory profiles of B-ALL patients showing aberrant T/natural killer (NK) cell antigen expression. Materials and methods This is a prospective study where 152 consecutive B-ALL patients were analyzed for aberrant expression of T/NK cell antigens (CD1a, CD5, CD4, CD7, CD8 and CD56) by FCI. The clinical and laboratory profile of these T/NK-cell antigen-expressing B-ALL patients was statistically analyzed against conventional B-ALL patients. Results In our B-ALL cohort, CD5, CD7 and CD56 expression were observed in one, six and nine patients, respectively. CD56-expressing B-ALL patients were predominantly children (89%) and presented as standard clinical risk (p = 0.010) disease with frequent ETV6-RUNX1 fusion (p = 0.021) positivity. On the contrary, CD7-expressing B-ALL patients were adolescent-young adult/adult-age skewed (83%) and had an adverse cytogenetic profile (p = 0.001), especially for the frequent presence of BCR-ABL1 fusion (p = 0.004) and KMT2A rearrangement (p = 0.045). CD7-expressing B-ALL patients had inferior event-free survival (p = 0.040) than their CD56-expressing counterparts, but there was no significant difference in the overall survival (p = 0.317). Conclusion In comparison to conventional B-ALL patients, there are significant differences in the age, cytogenetic profile and event-free survival of T/NK-cell antigen-expressing B-ALL patients.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Flow Cytometry Type of study: Observational study / Risk factors / Systematic reviews Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Language: English Journal: Hematol., Transfus. Cell Ther. (Impr.) Journal subject: Hematologia / TransfusÆo de Sangue Year: 2022 Type: Article Affiliation country: India Institution/Affiliation country: Cancer Institute (W.I.A.)/IN

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Flow Cytometry Type of study: Observational study / Risk factors / Systematic reviews Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Language: English Journal: Hematol., Transfus. Cell Ther. (Impr.) Journal subject: Hematologia / TransfusÆo de Sangue Year: 2022 Type: Article Affiliation country: India Institution/Affiliation country: Cancer Institute (W.I.A.)/IN